Topics:
Hematologic Malignancies • Medical Oncology • Lymphoma • ASCO Journal Club • Non-Hodgkin Lymphoma • Hematology • Mantle Cell Lymphoma
Are there biomarkers or other factors to help predict which patients with MCL are most likely to benefit, or not, from pirtobrutinib following a prior covalent BTKi?
How do you predict which patients may be in a high risk group and less likely to benefit from a second BTKi?
Answer from: Medical Oncologist at Academic Institution
In the phase I/II BRUIN trial, responses with pirtobrutinib occurred across prespecified subgroups regardless of demographics, number of prior lines of therapy, or prior therapy. Responses were seen in patients with blastoid and pleomorphic histology, regardless of the number of prior lines of thera...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Interestingly, there were no specific or identifiable characteristics that helped predict patients who are responders from non-responders to pirtobrutinib. There was no difference in ORR by prior exposure to stem cell transplant, CAR-T, presence of p53 mutation, histology, or ki67%. Not surprisingly...